Zacks Research Weighs in on GSK’s Q1 Earnings (NYSE:GSK)

GSK plc (NYSE:GSK) – Stock analysts at Zacks Research cut their Q1 2025 earnings per share (EPS) estimates for shares of GSK in a research report issued to clients and investors on Wednesday, February 26th. Zacks Research analyst E. Bagri now forecasts that the pharmaceutical company will post earnings of $1.03 per share for the quarter, down from their previous forecast of $1.10. The consensus estimate for GSK’s current full-year earnings is $4.14 per share. Zacks Research also issued estimates for GSK’s Q2 2025 earnings at $1.05 EPS, Q3 2025 earnings at $1.24 EPS, Q1 2026 earnings at $1.05 EPS, Q2 2026 earnings at $1.10 EPS, Q3 2026 earnings at $1.48 EPS, FY2026 earnings at $4.64 EPS and FY2027 earnings at $5.04 EPS.

A number of other research firms have also commented on GSK. StockNews.com upgraded GSK from a “buy” rating to a “strong-buy” rating in a research note on Friday, February 7th. Deutsche Bank Aktiengesellschaft cut shares of GSK from a “buy” rating to a “hold” rating in a research report on Friday, November 15th. Morgan Stanley initiated coverage on shares of GSK in a report on Wednesday, February 12th. They issued an “equal weight” rating on the stock. Jefferies Financial Group downgraded shares of GSK from a “buy” rating to a “hold” rating and cut their price target for the stock from $53.00 to $39.50 in a report on Tuesday, November 12th. Finally, Guggenheim cut shares of GSK from a “buy” rating to a “neutral” rating in a research note on Thursday, October 31st. Seven equities research analysts have rated the stock with a hold rating and four have issued a strong buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $43.25.

GSK Stock Down 0.2 %

NYSE GSK opened at $37.33 on Friday. The company has a current ratio of 0.78, a quick ratio of 0.52 and a debt-to-equity ratio of 1.12. The company has a market cap of $77.36 billion, a price-to-earnings ratio of 23.47, a PEG ratio of 1.12 and a beta of 0.64. The company has a 50 day moving average of $34.91 and a 200-day moving average of $37.30. GSK has a 1-year low of $31.72 and a 1-year high of $45.92.

GSK (NYSE:GSK) last released its quarterly earnings results on Wednesday, February 5th. The pharmaceutical company reported $0.59 EPS for the quarter, beating the consensus estimate of $0.44 by $0.15. GSK had a net margin of 8.13% and a return on equity of 48.59%.

Institutional Trading of GSK

Several hedge funds and other institutional investors have recently made changes to their positions in GSK. FMR LLC raised its stake in shares of GSK by 82.1% during the fourth quarter. FMR LLC now owns 52,823,032 shares of the pharmaceutical company’s stock valued at $1,786,475,000 after acquiring an additional 23,814,104 shares during the last quarter. Primecap Management Co. CA raised its position in GSK by 70.1% during the 4th quarter. Primecap Management Co. CA now owns 25,261,660 shares of the pharmaceutical company’s stock worth $854,349,000 after purchasing an additional 10,407,905 shares during the last quarter. Voloridge Investment Management LLC lifted its holdings in GSK by 1,360.4% during the 4th quarter. Voloridge Investment Management LLC now owns 2,165,043 shares of the pharmaceutical company’s stock worth $73,222,000 after buying an additional 2,016,795 shares during the period. Bridgewater Associates LP grew its position in shares of GSK by 132.7% in the 4th quarter. Bridgewater Associates LP now owns 2,247,691 shares of the pharmaceutical company’s stock valued at $76,017,000 after buying an additional 1,281,855 shares during the last quarter. Finally, Woodline Partners LP bought a new stake in shares of GSK in the 4th quarter valued at about $36,665,000. 15.74% of the stock is currently owned by institutional investors.

GSK Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, April 10th. Stockholders of record on Friday, February 21st will be issued a dividend of $0.3932 per share. The ex-dividend date of this dividend is Friday, February 21st. This is an increase from GSK’s previous quarterly dividend of $0.39. This represents a $1.57 annualized dividend and a dividend yield of 4.21%. GSK’s dividend payout ratio is 98.74%.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.